Literature DB >> 24202856

The use of digital images improves reproducibility of the ki-67 labeling index as a proliferation marker in breast cancer.

András Vörös1, Erika Csörgő, Bence Kővári, Péter Lázár, Gyöngyi Kelemen, Gábor Cserni.   

Abstract

The proportion of Ki-67 immunostained cells (Ki-67 labeling index, LI) is one of the most commonly used histology methods for estimating proliferation of breast carcinomas. Although the Ki-67 LI is used in treatment decision making, its reproducibility shows variation in different studies, and is generally less then optimal. The aim of the present study was to investigate how the use of a standardized, partially digitalized counting method could affect reproducibility of determining the Ki-67 LI. Thirty breast cancer core-biopsy samples were stained with B-56, SP-6 and MIB-1 monoclonal Ki-67 antibodies. Each sample was represented by a single digital photograph taken with a x20 objective. Four investigators determined the Ki-67 LI on these digital images by estimation, then by counting with the help of a grid overlaid on the same images. Altogether 720 evaluations were made by 4 independent pathologists. Good to excellent correlation was found between estimations and calculations of each observer. Kappa values >0.6 suggest substantial inter-observer agreement when classifying the cases into a 15 % and 30 % cut-off determined three-tiered or a 4-quarter-based four-tiered categorization, which is better than the fair reproducibility gained on the real slides in a previous study. The results also suggest that the type of the antibody may also impact on the consistency of both estimating and calculating the Ki-67 LIs. The results indicate that counting on digital images may significantly improve reproducibility of determining the KI-67 LI. Interestingly, estimation on the same images is not worse, but is obviously faster and more convenient.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24202856     DOI: 10.1007/s12253-013-9708-z

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  31 in total

1.  St. Gallen 2011: Summary of the Consensus Discussion.

Authors:  Michael Gnant; Nadia Harbeck; Christoph Thomssen
Journal:  Breast Care (Basel)       Date:  2011-04-29       Impact factor: 2.860

2.  Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer.

Authors:  S Liu; S M Edgerton; D H Moore; A D Thor
Journal:  Clin Cancer Res       Date:  2001-06       Impact factor: 12.531

3.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

4.  The prognostic value of proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67.

Authors:  W H Goodson; D H Moore; B M Ljung; K Chew; B Mayall; H S Smith; F M Waldman
Journal:  Breast Cancer Res Treat       Date:  2000-01       Impact factor: 4.872

Review 5.  Ki67 in breast cancer: prognostic and predictive potential.

Authors:  Rinat Yerushalmi; Ryan Woods; Peter M Ravdin; Malcolm M Hayes; Karen A Gelmon
Journal:  Lancet Oncol       Date:  2010-02       Impact factor: 41.316

6.  Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies.

Authors:  S Fasanella; E Leonardi; C Cantaloni; C Eccher; I Bazzanella; D Aldovini; E Bragantini; L Morelli; L V Cuorvo; A Ferro; F Gasperetti; G Berlanda; P Dalla Palma; M Barbareschi
Journal:  Diagn Pathol       Date:  2011-03-30       Impact factor: 2.644

Review 7.  Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review.

Authors:  Elisabeth Luporsi; Fabrice André; Frédérique Spyratos; Pierre-Marie Martin; Jocelyne Jacquemier; Frédérique Penault-Llorca; Nicole Tubiana-Mathieu; Brigitte Sigal-Zafrani; Laurent Arnould; Anne Gompel; Caroline Egele; Bruno Poulet; Krishna B Clough; Hubert Crouet; Alain Fourquet; Jean-Pierre Lefranc; Carole Mathelin; Nicolas Rouyer; Daniel Serin; Marc Spielmann; Margaret Haugh; Marie-Pierre Chenard; Etienne Brain; Patricia de Cremoux; Jean-Pierre Bellocq
Journal:  Breast Cancer Res Treat       Date:  2011-11-03       Impact factor: 4.872

8.  How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists.

Authors:  Zsuzsanna Varga; Joachim Diebold; Corina Dommann-Scherrer; Harald Frick; Daniela Kaup; Aurelia Noske; Ellen Obermann; Christian Ohlschlegel; Barbara Padberg; Christiane Rakozy; Sara Sancho Oliver; Sylviane Schobinger-Clement; Heide Schreiber-Facklam; Gad Singer; Coya Tapia; Urs Wagner; Mauro G Mastropasqua; Giuseppe Viale; Hans-Anton Lehr
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

9.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.

Authors:  A Goldhirsch; J N Ingle; R D Gelber; A S Coates; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2009-06-17       Impact factor: 32.976

10.  Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.

Authors:  E de Azambuja; F Cardoso; G de Castro; M Colozza; M S Mano; V Durbecq; C Sotiriou; D Larsimont; M J Piccart-Gebhart; M Paesmans
Journal:  Br J Cancer       Date:  2007-04-24       Impact factor: 7.640

View more
  7 in total

1.  Different methods of pretreatment Ki-67 labeling index evaluation in core biopsies of breast cancer patients treated with neoadjuvant chemotherapy and their relation to response to therapy.

Authors:  András Vörös; Erika Csörgő; Bence Kővári; Péter Lázár; Gyöngyi Kelemen; Orsolya Rusz; Tibor Nyári; Gábor Cserni
Journal:  Pathol Oncol Res       Date:  2014-05-25       Impact factor: 3.201

2.  Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.

Authors:  Shalaka Joshi; Johnathan Watkins; Patrycja Gazinska; John P Brown; Cheryl E Gillett; Anita Grigoriadis; Sarah E Pinder
Journal:  BMC Cancer       Date:  2015-07-25       Impact factor: 4.430

3.  Can ki-67 play a role in prediction of breast cancer patients' response to neoadjuvant chemotherapy?

Authors:  Juhasz-Böss Ingolf; Mavrova Russalina; Moga Simona; Radosa Julia; Schmidt Gilda; Rainer M Bohle; Hasenfus Andrea; Solomayer Erich; Herr Daniel
Journal:  Biomed Res Int       Date:  2014-03-25       Impact factor: 3.411

4.  Quantum dots-based quantitative and in situ multiple imaging on ki67 and cytokeratin to improve ki67 assessment in breast cancer.

Authors:  Jing Ping Yuan; Lin Wei Wang; Ai Ping Qu; Jia Mei Chen; Qing Ming Xiang; Chuang Chen; Sheng-Rong Sun; Dai-Wen Pang; Juan Liu; Yan Li
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240

5.  A Comparison of Visual Assessment and Automated Digital Image Analysis of Ki67 Labeling Index in Breast Cancer.

Authors:  Fangfang Zhong; Rui Bi; Baohua Yu; Fei Yang; Wentao Yang; Ruohong Shui
Journal:  PLoS One       Date:  2016-02-29       Impact factor: 3.240

6.  Practical approaches to automated digital image analysis of Ki-67 labeling index in 997 breast carcinomas and causes of discordance with visual assessment.

Authors:  Ah-Young Kwon; Ha Young Park; Jiyeon Hyeon; Seok Jin Nam; Seok Won Kim; Jeong Eon Lee; Jong-Han Yu; Se Kyung Lee; Soo Youn Cho; Eun Yoon Cho
Journal:  PLoS One       Date:  2019-02-20       Impact factor: 3.240

7.  Quantum dots-based double imaging combined with organic dye imaging to establish an automatic computerized method for cancer Ki67 measurement.

Authors:  Lin-Wei Wang; Ai-Ping Qu; Wen-Lou Liu; Jia-Mei Chen; Jing-Ping Yuan; Han Wu; Yan Li; Juan Liu
Journal:  Sci Rep       Date:  2016-02-03       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.